ROLE OF CONCENTRATION-RESPONSE MODELING WITH PHASE I DATA IN EVALUATING QT INTERVAL PROLONGATION: RESULTS WITH TEN COMPOUNDS.

被引：0
|
作者：
Huh, Y. [1 ]
Byon, W. [2 ]
Riley, S. P. [2 ]
机构：
[1] Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA
[2] Pfizer Inc, Groton, CT 06340 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2013年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S52 / S52
页数：1
相关论文
共 12 条
  • [1] Role of Concentration-Response Modeling with Phase I Data in Evaluating QT Interval Prolongation: Results with Ten Compounds
    Huh, Yeamin
    Byon, Wonkyung
    Riley, Steve
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2013, 40 : S65 - S65
  • [2] Concentration-response modeling of ECG data from early-phase clinical studies to assess QT prolongation risk of contezolid (MRX-I), an oxazolidinone antibacterial agent
    Wu, Junzhen
    Wang, Kun
    Chen, Yuancheng
    Yuan, Hong
    Li, Li
    Zhang, Jing
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2019, 46 (06) : 531 - 541
  • [3] Assessing QT/QTc interval prolongation with concentration-QT modeling for Phase I studies: impact of computational platforms, model structures and confidence interval calculation methods
    Lu, Jingtao
    Li, Jianguo
    Helmlinger, Gabriel
    Al-Huniti, Nidal
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 (03) : 469 - 482
  • [4] Assessing QT/QTc interval prolongation with concentration-QT modeling for Phase I studies: impact of computational platforms, model structures and confidence interval calculation methods
    Jingtao Lu
    Jianguo Li
    Gabriel Helmlinger
    Nidal Al-Huniti
    Journal of Pharmacokinetics and Pharmacodynamics, 2018, 45 : 469 - 482
  • [5] Concentration–response modeling of ECG data from early-phase clinical studies to assess QT prolongation risk of contezolid (MRX-I), an oxazolidinone antibacterial agent
    Junzhen Wu
    Kun Wang
    Yuancheng Chen
    Hong Yuan
    Li Li
    Jing Zhang
    Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46 : 531 - 541
  • [6] No QT interval prolongation effect of sepiapterin: a concentration-QTc analysis of pooled data from phase 1 and phase 3 studies in healthy volunteers and patients with phenylketonuria
    Gao, Lan
    Hu, Yongjun
    Smith, Neil
    Uvarov, Artem
    Peyret, Thomas
    Gosselin, Nathalie H.
    Kong, Ronald
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2025, 52 (01)
  • [7] Concentration-Response Modeling of ECG Data From Early-Phase Clinical Studies as an Alternative Clinical and Regulatory Approach to Assessing QT Risk Experience From the Development Program of Lemborexant
    Murphy, Patricia J.
    Yasuda, Sanae
    Nakai, Kenya
    Yoshinaga, Takashi
    Hall, Nancy
    Zhou, Meijian
    Aluri, Jagadeesh
    Rege, Bhaskar
    Moline, Margaret
    Ferry, Jim
    Darpo, Borje
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (01): : 96 - 104
  • [8] Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies
    Helen Swaisland
    Ruth Plummer
    Karen So
    Sally Garnett
    Wendy Bannister
    Marc-Antoine Fabre
    Corina Dota
    Anitra Fielding
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 775 - 784
  • [9] Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies
    Swaisland, Helen
    Plummer, Ruth
    So, Karen
    Garnett, Sally
    Bannister, Wendy
    Fabre, Marc-Antoine
    Dota, Corina
    Fielding, Anitra
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (04) : 775 - 784
  • [10] Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure-Response Analysis
    Lagishetty, Chakradhar
    Moore, Katy
    Ackerman, Peter
    Llamoso, Cyril
    Magee, Mindy
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (04): : 769 - 776
12